| Cover | 6 Months Ended |
| Jun. 30, 2021 | |
| Cover [Abstract] | |
| Document Type | 6-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 30, 2021 |
| Document Fiscal Period Focus | Q2 |
| Document Fiscal Year Focus | 2021 |
| Current Fiscal Year End Date | --12-31 |
| Entity File Number | 001-36345 |
| Entity Registrant Name | GALMED PHARMACEUTICALS LTD. |
| Entity Central Index Key | 0001595353 |
| Entity Address, Address Line One | 16 Tiomkin St. |
| Entity Address, City or Town | Tel Aviv |
| Entity Address, Country | IL |
| Entity Address, Postal Zip Code | 6578317 |
| Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
| Current assets | ||
| Cash and cash equivalents | $ 7,923 | $ 6,947 |
| Restricted Cash | 113 | 113 |
| Short-term deposits | 1,809 | 3,807 |
| Marketable debt securities | 41,333 | 40,132 |
| Other receivable | 487 | 812 |
| Total current assets | 51,665 | 51,811 |
| Right of use assets | 497 | 394 |
| Property and equipment, net | 163 | 176 |
| Total non-current assets | 660 | 570 |
| Total assets | 52,325 | 52,381 |
| Current liabilities | ||
| Trade payables | 5,629 | 7,046 |
| Other payables | 1,379 | 966 |
| Total current liabilities | 7,008 | 8,012 |
| Non-current liabilities | ||
| Lease obligation | 318 | 216 |
| Total non-current liabilities | 318 | 216 |
| Ordinary shares par value NIS 0.01 per share; Authorized 50,000,000; Issued and outstanding: 25,083,914 shares as of June 30, 2021; 21,325,975 shares as of December 31, 2020 | 70 | 58 |
| Additional paid-in capital | 197,829 | 179,530 |
| Accumulated other comprehensive gain | 108 | 272 |
| Accumulated deficit | (153,008) | (135,707) |
| Total stockholders’ equity | 44,999 | 44,153 |
| Total liabilities and stockholders’ equity | $ 52,325 | $ 52,381 |
| Consolidated Balance Sheets (Unaudited) (Parenthetical) - ₪ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
| Statement of Financial Position [Abstract] | ||
| Ordinary shares, price per share | ₪ 0.01 | ₪ 0.01 |
| Ordinary shares, authorized | 50,000,000 | 50,000,000 |
| Ordinary shares, Issued | 25,083,914 | 21,325,975 |
| Ordinary shares, Outstanding | 25,083,914 | 21,325,975 |
| Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
| Income Statement [Abstract] | ||||
| Research and development expenses | $ 7,036 | $ 4,971 | $ 14,416 | $ 10,521 |
| General and administrative expenses | 1,376 | 845 | 3,128 | 1,757 |
| Total operating expenses | 8,412 | 5,816 | 17,544 | 12,278 |
| Financial income, net | (16) | (290) | (243) | (689) |
| Net loss | $ 8,396 | $ 5,526 | $ 17,301 | $ 11,589 |
| Basic and diluted net loss per share | $ 0.33 | $ 0.26 | $ 0.72 | $ 0.55 |
| Weighted-average number of shares outstanding used in computing basic and diluted net loss per share | 25,083,914 | 21,153,166 | 24,099,132 | 21,152,003 |
| Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
| Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
| Income Statement [Abstract] | ||||
| Net loss | $ 8,396 | $ 5,526 | $ 17,301 | $ 11,589 |
| Other comprehensive loss: | ||||
| Net unrealized loss (gain) on available for sale securities | 34 | (725) | 164 | (463) |
| Comprehensive loss | $ 8,430 | $ 4,801 | $ 17,465 | $ 11,126 |
| Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total | |||
| Beginning balance, value at Dec. 31, 2019 | $ 58 | $ 176,696 | $ 35 | $ (106,936) | $ 69,853 | |||
| Beginning balance, shares at Dec. 31, 2019 | 21,139,385 | |||||||
| Stock-based compensation | 515 | 515 | ||||||
| Exercise of options and restricted stock units | 61 | 61 | ||||||
| Exercise of options and restricted stock units, shares | 13,781 | |||||||
| Unrealized loss from marketable debt securities | (262) | (262) | ||||||
| Net loss | (6,063) | (6,063) | ||||||
| Ending balance, value at Mar. 31, 2020 | $ 58 | 177,272 | (227) | (112,999) | 64,104 | |||
| Ending balance, shares at Mar. 31, 2020 | 21,153,166 | |||||||
| Beginning balance, value at Dec. 31, 2019 | $ 58 | 176,696 | 35 | (106,936) | 69,853 | |||
| Beginning balance, shares at Dec. 31, 2019 | 21,139,385 | |||||||
| Net loss | (11,589) | |||||||
| Ending balance, value at Jun. 30, 2020 | $ 58 | 177,853 | 498 | 118,525 | 59,884 | |||
| Ending balance, shares at Jun. 30, 2020 | 21,153,166 | |||||||
| Beginning balance, value at Mar. 31, 2020 | $ 58 | 177,272 | (227) | (112,999) | 64,104 | |||
| Beginning balance, shares at Mar. 31, 2020 | 21,153,166 | |||||||
| Stock-based compensation | 581 | 581 | ||||||
| Unrealized loss from marketable debt securities | 725 | 725 | ||||||
| Net loss | (5,526) | (5,526) | ||||||
| Ending balance, value at Jun. 30, 2020 | $ 58 | 177,853 | 498 | 118,525 | 59,884 | |||
| Ending balance, shares at Jun. 30, 2020 | 21,153,166 | |||||||
| Beginning balance, value at Dec. 31, 2020 | $ 58 | 179,530 | 272 | (135,707) | 44,153 | |||
| Beginning balance, shares at Dec. 31, 2020 | 21,325,975 | |||||||
| Stock-based compensation | 471 | 471 | ||||||
| Share issuance | $ 12 | 17,356 | 17,368 | |||||
| Share issuance, shares | 3,739,203 | |||||||
| Exercise of options | [2] | [1] | [1] | |||||
| Exercise of options, shares | [2] | 18,736 | ||||||
| Unrealized loss from marketable debt securities | (130) | (130) | ||||||
| Net loss | (8,905) | (8,905) | ||||||
| Ending balance, value at Mar. 31, 2021 | $ 70 | 197,357 | 142 | (144,612) | 52,957 | |||
| Ending balance, shares at Mar. 31, 2021 | 25,083,914 | |||||||
| Beginning balance, value at Dec. 31, 2020 | $ 58 | 179,530 | 272 | (135,707) | 44,153 | |||
| Beginning balance, shares at Dec. 31, 2020 | 21,325,975 | |||||||
| Net loss | (17,301) | |||||||
| Ending balance, value at Jun. 30, 2021 | $ 70 | 197,829 | 108 | (153,008) | 44,999 | |||
| Ending balance, shares at Jun. 30, 2021 | 25,083,914 | |||||||
| Beginning balance, value at Mar. 31, 2021 | $ 70 | 197,357 | 142 | (144,612) | 52,957 | |||
| Beginning balance, shares at Mar. 31, 2021 | 25,083,914 | |||||||
| Stock-based compensation | 472 | 472 | ||||||
| Unrealized loss from marketable debt securities | (34) | (34) | ||||||
| Net loss | (8,396) | (8,396) | ||||||
| Ending balance, value at Jun. 30, 2021 | $ 70 | $ 197,829 | $ 108 | $ (153,008) | $ 44,999 | |||
| Ending balance, shares at Jun. 30, 2021 | 25,083,914 | |||||||
| [1] | Represents amount less than $1. | |||||||
| [2] | See notes 3.3 and 3.4. | |||||||
| Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |||
| Jun. 30, 2021 | Jun. 30, 2020 | |||
| Cash flow from operating activities | ||||
| Net loss | $ (17,301) | $ (11,589) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities | ||||
| Depreciation and amortization | 21 | 19 | ||
| Stock-based compensation expense | 943 | 1,096 | ||
| Amortization of premium on marketable debt securities | 126 | 16 | ||
| Interest income from short-term deposits | (7) | (268) | ||
| Gain from realization of marketable debt securities | (19) | (10) | ||
| Changes in operating assets and liabilities: | ||||
| Decrease in other accounts receivable | 325 | 158 | ||
| Decrease in trade payables | (1,417) | (2,123) | ||
| Increase (decrease) in other accounts payable | 412 | (141) | ||
| Net cash used in operating activities | (16,917) | (12,842) | ||
| Cash flow from investing activities | ||||
| Purchase of property and equipment | (8) | (5) | ||
| Investment in available for sale securities | (7,831) | (26,979) | ||
| Sale (investment) in short term deposits, net | 2,005 | (4,000) | ||
| Maturity of short term deposits | 4,800 | |||
| Consideration from sale of available for sale securities | 6,359 | 28,588 | ||
| Net cash provided by (used in) investing activities | 525 | 2,404 | ||
| Cash flow from financing activities | ||||
| Proceeds from exercise of options (*) | [1] | 61 | ||
| Issuance of Ordinary shares, net of issuance cost (**) | [2] | 17,368 | ||
| Net cash provided in financing activities | 17,368 | 61 | ||
| Increase (decrease) in cash and cash equivalents and restricted cash | 976 | (10,377) | ||
| Cash and cash equivalents and restricted cash at the beginning of the period | 7,060 | 16,043 | ||
| Cash and cash equivalents and restricted cash at the end of the period | 8,036 | 5,666 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash received from interest | 347 | 317 | ||
| Non-cash transactions: | ||||
| Recognition of right-of-use asset and lease liability from adoption of ASU 2016-02 | $ 530 | $ 35 | ||
| [1] | Represents amount less than $1. | |||
| [2] | See notes 3.3 and 3.4. | |||
| Basis of presentation | 6 Months Ended |
| Jun. 30, 2021 | |
| Accounting Policies [Abstract] | |
| Basis of presentation | Note 1 - Basis of presentation Galmed Pharmaceuticals Ltd. (the “Company”) is a clinical-stage biopharmaceutical company primarily focused on the development of therapeutics for the treatment of liver diseases. The Company was incorporated in Israel on July 31, 2013 and commenced operations on February 2, 2014. The Company holds a wholly-owned subsidiary, Galmed International Ltd., which was incorporated in Malta. Galmed International Ltd. previously held a wholly-owned subsidiary, Galmed Medical Research Ltd., which was liquidated during the first quarter of 2019. The Company also holds two additional wholly-owned subsidiaries, Galmed Research and Development Ltd and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. These unaudited interim consolidated financial statements have been prepared as of June 30, 2021 and for the three and six months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2020 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 18, 2021 (the “Annual Report”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2021. |
| Summary of significant accounting policies | 6 Months Ended |
| Jun. 30, 2021 | |
| Accounting Policies [Abstract] | |
| Summary of significant accounting policies | Note 2 - Summary of significant accounting policies The significant accounting policies that have been applied in the preparation of the unaudited consolidated interim financial statements are identical to those that were applied in preparation of the Company’s interim most recent annual financial statements in connection with its Annual Report on Form 20-F. |
| Stockholders’ Equity | 6 Months Ended |
| Jun. 30, 2021 | |
| Equity [Abstract] | |
| Stockholders’ Equity | Note 3 - Stockholders’ Equity 1. During the six months ended June 30, 2021, certain office holders exercised options into 18,736 0.01 total amount of less than $1 thousand 2. During February 2021, the Company entered into an underwriting agreement with Cantor Fitzgerald & Co. as underwriter, in connection with an underwritten public offering of 2,197,803 4.3258 9.3 3. On March 16, 2021, the Company granted options to purchase 45,000 ordinary shares of the Company to an employee and a consultant. The options are exercisable at $ 4.16 per share, have a 10 -year term and vest over a period of four years. The aggregate grant date fair value of such options was approximately $ 0.1 million. 4. On May 15, 2020, the Company amended and restated the Sales Agreement dated December 22, 2017 between the Company and Stifel, Nicolaus & Company, Incorporated to include Cantor Fitzgerald & Co. as an additional sales agent for the Company’s “at the market offering” program (the “A&R Sales Agreement”). During February 2021, the Company sold an additional 1,541,400 8.1 5. On March 26, 2021, the Company entered into a new Sales Agreement with Cantor Fitzgerald & Co. and Canaccord Genuity LLC, as sales agents, pursuant to which the Company may offer and sell ordinary shares “at the market” having an aggregate offering price of up to $ 50.0 6. On July 15, 2021, subsequent to the balance sheet date, the Company granted options to purchase 100,000 ordinary shares of the Company to its non-management directors. The options are exercisable at $ 3.10 per share, have a 10 -year term and vest over a period of three years. The grant is subject to the approval at the Company’s general shareholders meeting. |
| Significant events during the reporting period | 6 Months Ended |
| Jun. 30, 2021 | |
| Significant Events During Reporting Period | |
| Significant events during the reporting period | Note 4 - Significant events during the reporting period On June 28, 2021, the Company entered into a license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to which Yissum granted to the Company a worldwide, exclusive and irrevocable license to develop and commercialize Amilo-5Mer. The grant of the license takes effect upon approval of the Israel Innovation Authority. Under the license agreement, the Company shall be responsible for carrying out the development and commercialization of Amilo-5Mer and the prosecution and maintenance of the licensed patents under the license agreement. In consideration for the grant of the license, the Company has agreed to pay to Yissum an upfront license fee of $ 100,000 850,000 |
| Stockholders’ Equity (Details Narrative) $ / shares in Units, $ in Millions | Jul. 15, 2021$ / sharesshares | Mar. 26, 2021USD ($) | Mar. 16, 2021USD ($)$ / sharesshares | Feb. 28, 2021USD ($)$ / sharesshares | Jun. 30, 2021₪ / sharesshares | Dec. 31, 2020₪ / shares |
| Entity Listings [Line Items] | ||||||
| Ordinary shares, price per share | ₪ / shares | ₪ 0.01 | ₪ 0.01 | ||||
| Underwriting Agreement [Member] | Cantor Fitzgerald & Co [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Number of shares issued during period | 2,197,803,000 | |||||
| Share issued, price per share | $ / shares | $ 4.3258 | |||||
| Proceeds from public offering | $ | $ 9.3 | |||||
| ATM Program [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Number of shares sold during period | 1,541,400 | |||||
| Proceeds from sale of stock | $ | $ 8.1 | |||||
| Sales Agreement [Member] | Cantor Fitzgerald & Co. and Canaccord Genuity LLC [Member] | Maximum [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Proceeds from public offering | $ | $ 50 | |||||
| Office Holders [Member] | Exercised of Options [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Number of shares issued during period | 18,736 | |||||
| Ordinary shares, price per share | ₪ / shares | ₪ 0.01 | |||||
| Shares value, description | total amount of less than $1 thousand | |||||
| Employee and Consultant [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 45,000 | |||||
| Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | $ / shares | $ 4.16 | |||||
| Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term | 10 years | |||||
| Stock Issued During Period, Value, Stock Options Exercised | $ | $ 0.1 | |||||
| Non-Management Directors [Member] | Subsequent Event [Member] | ||||||
| Entity Listings [Line Items] | ||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 100,000 | |||||
| Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | $ / shares | $ 3.10 | |||||
| Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term | 10 years |
| Significant events during the reporting period (Details Narrative) | Jun. 28, 2021USD ($) |
| SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items] | |
| Upfront license fee | $ 100,000 |
| Maximum [Member] | |
| SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items] | |
| Payments to regulatory milestones | $ 850,000 |
